Haleon completes tranche of buyback, updates outstanding voting shares

Rhea-AI Filing Summary

Haleon plc reports the purchase and cancellation of 1,504,400 ordinary shares of
each under the second tranche of its share buyback programme announced 31 July 2025. Trades executed on 18 August 2025 via London Stock Exchange CBOE (UK)/CXE at an average price of 358.0459 per share. After settlement, registered share capital is 8,971,802,095 ordinary shares, with 3,880,205 held as treasury shares, leaving 8,967,921,890 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided RNS link and on the company website.

Positive

• Buyback executed and shares cancelled, demonstrating follow-through on the announced repurchase programme
• Regulatory disclosure provided with trade-level breakdown available and updated voting share count for shareholder notification

Negative

• None.

Insights

Securities Analyst

TL;DR: Completed tranche of announced buyback; shrinkage of share count is immaterial to valuation but supports shareholder return policy.

Haleon has executed and cancelled 1.5044 million shares under its previously announced repurchase programme, reducing the registered share capital and updating the count of voting shares. The absolute scale of the cancellation versus roughly 8.97 billion shares outstanding is very small, implying negligible immediate EPS or ownership impact. The company provided the regulatory trade breakdown link, meeting Market Abuse Regulation disclosure requirements.

Corporate Governance Expert

TL;DR: Procedural disclosure appears compliant; share cancellation and updated voting figure disclosed for shareholder notification purposes.

The announcement supplies the updated registered capital and voting share total and references availability of the trade-level breakdown. This aligns with disclosure norms under the FCAs rules and the Market Abuse Regulation as applied in the UK. There are no governance red flags in the text; details on programme size or remaining capacity are not included in this filing.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	19 August 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

19 August 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,504,400 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	18 August 2025	18 August 2025	18 August 2025
Number of Shares purchased:	1,504,400	-	-
Highest price paid per Share (p):	359.8000	-	-
Lowest price paid per Share (p):	356.1000	-	-
Volume weighted average price paid per Share (p):	358.0459	-	-

Following the settlement of the above, the Company's registered share capital is 8,971,802,095 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,967,921,890 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/7938V_1-2025-8-18.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: August 19, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What shares did Haleon (HLN) purchase on 18 August 2025?

Haleon purchased and cancelled 1,504,400 ordinary shares on 18 August 2025 under the second tranche of its buyback programme.

How many voting shares does Haleon (HLN) have after this cancellation?

After settlement the number of ordinary shares with voting rights is 8,967,921,890.

Where can I find the full breakdown of the individual trades?

A full breakdown is available at the RNS link provided in the filing: http://www.rns-pdf.londonstockexchange.com/rns/7938V_1-2025-8-18.pdf and on www.haleon.com/investors.

How many shares are held as treasury stock after the transaction?

The filing states 3,880,205 ordinary shares are held as treasury shares.

Does this filing provide details on the remaining buyback programme capacity?

No. The filing confirms this tranche was executed and cancelled but does not state remaining programme size or available capacity.